Early treatment of mild covid cases have been identified by the IATF as crucial in preventing the cases into escalating into moderate and severe cases thus prevent over- burdening the country's healthcare system.
Recuenco General Hospital in Taguig City is a typical example of a Level 1 hospital at the frontlines of mild cases that have to be taken cared of to prevent them from escalating to severe cases.
Cabinet Secretary Karlo Nograles co-chairperson of the IATF turns over Cocolicious VCO to officers of Recuenco General Hospital in Taguig City led by Dr Angel Prodigalidad II Asst Hospital Administrator , Admin OIC Vivian Recuenco and Admin staff Sarie Ann Dela Cruz.
Cocolicious CEO Reynaldo Pacheco shared to Dr Prodigalidad the highlights and insights of the DOST-FNRI VCO Clinical study, the health benefits of VCO as "contra covid" supplemental treatment and the simple ways to use VCO such as mixing in meals, drinking 1 tablespoon during meals, oil pulling (as mouthwash 1tbsp for 10 mins), applying to the nostrils, and rubbing to the skin armpits and neck.
Pacheco also cited from the recent DOST-FNRI VCO Clinical study that VCO is effective for mild covid cases as "anti-infection and anti-inflammatory" as shown by the drop in C-Reactive Protein (CRP) to within normal levels of the patients in the DOST study. Clinical trials for moderate and severe cases are underway in the PGH.
Cocolicious together with the VCOP, the VCO association of producers and traders, has partnered with the IATF to distribute Cocolicious VCO to level 1 hospitals and community isolation facilities.
NOTE: COCOLICIOUS IS A DIETARY SUPPLEMENT APPROVED BY THE FDA. IT IS NOT A DRUG AND SHOULD NOT BE USED AS A DRUG TO TREAT ANY DISEASE.